Published on
Last updated on
2022 Sampling Inspection Plan for Medical Devices
2022 Sampling Inspection Plan was published (No.15-2022) by the NMPA (National Medical Products Administration) on February 22, 2022, for medical devices covering 60 products including electronic endoscope, hollow fiber dialyzer, sodium hyaluronate injection, etc.
Highlights - 2022 sampling inspection plan
- The main focus of this year’s sampling inspection plan targets medical electrical equipment, in vitro diagnostic reagents, anti-epidemic medical supplies, etc.
- If there is any objection against the inspection results, only one chance will be given to appeal whilst the application for re-inspection should be submitted within 7 days after receiving the results. However, there will be no arrangement available for re-inspection for oxygenerators, and 4 other products that require risk monitoring sampling inspections.
- Re-inspection applications would be accepted and handled by the MPA of the respective province where the registrant, filer or legal agent belongs to.
- The registrant, filer or legal agent should take immediate actions to carry out risk control measures once they receive a failure report from the sampling inspection
By Julie Zhang and Jacky Li. Contact Cisema if you would like to learn more.
Related News
Malaysia Introduces New e-IFU & Digital Labelling Guidance for Medical Devices
Malaysia’s MDA publishes the 7th edition of guidance on medical device labelling, with new e-labelling, e-IFU, and accessibility requirements
Vietnam Authorities Step Up Cosmetic Recalls as Enforcement Tightens
Vietnam’s Drug Administration (DAV) is stepping up cosmetic product recalls as post-market surveillance tightens.
BPOM Clarifies Indonesia–US Trade Agreement Impact on Pharmaceutical Regulation
BPOM confirms pharmaceutical authorization, GMP oversight, and regulatory authority remain unchanged under the Indonesia–US trade agreement.